Principal Financial Group
RAPT

Principal Financial Group’s RAPT Therapeutics RAPT Stock Holding History

Principal Financial Group’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,111
Closed -$221K – 2479
2023
Q4 		$221K Buy
+1,111
New +$138K ﹤0.01% 2144

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Principal Financial Group's RAPT Position: Q1 2024 in Review

Principal Financial Group sold out of RAPT Therapeutics (RAPT) in Q1 2024, closing a stake of 1,111 shares — an estimated $221K sold.

Principal Financial Group first reported a position in RAPT in Q4 2023 and held it in 1 quarter. The position peaked at $221K in Q4 2023. 121 funds tracked by Wall St. Rank hold RAPT as of Q1 2024.

  • Principal Financial Group reported no remaining RAPT Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Principal Financial Group sold 1,111 RAPT Therapeutics shares in Q1 2024, an estimated $221K.
  • Principal Financial Group first reported a position in RAPT Therapeutics in Q4 2023 and held it in 1 quarter.
  • Principal Financial Group's RAPT Therapeutics position peaked at $221K in Q4 2023.
  • 121 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2024.

Based on Principal Financial Group's 13F filing for Q1 2024, filed 29 Apr 2024.